Medidata Adds Video eConsent
Medidata, a Dassault Systèmes company, announced the addition of myMedidata eConsent, which enables video visits with patients and study staff. With video eConsent, trial participants can engage in remote, face-to-face, live conversation between patients and clinical trial site staff during the informed consent process. This expansion of the company’s telemedicine/video visit capability is the most recent addition to the myMedidata portal designed to be a single patient platform for all patient-centered technology.
The benefits of enabling video interaction during eConsent include:
- Enhanced patient experience by allowing patients to engage with their clinical research team prior to consenting
- Improved consent tracking management, which reduces informed consent errors and eases the administrative burden for sites and study teams
- Accessibility through the myMedidata patient portal so that patients can virtually access all of their trial needs in one location with one login.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
